Phase III study to determine the efficacy of Durvalumab in combination with chemotherapy in completely resected stage II-III non-small cell lung cancer (NSCLC) - MERMAID-1

Study identifier:D910LC00001

ClinicalTrials.gov identifier:NCT04385368

EudraCT identifier:2020-000556-35

CTIS identifier:N/A

Study Complete

Official Title

A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)

Medical condition

Carcinoma, Non-Small-Cell Lung

Phase

Phase 3

Healthy volunteers

No

Study drug

Durvalumab + SoC chemotherapy

Sex

All

Actual Enrollment

89

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 17 Jul 2020
Primary Completion Date: 31 Aug 2023
Study Completion Date: 31 Aug 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria